Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery

JAMA Surg. 2023 Apr 1;158(4):339-340. doi: 10.1001/jamasurg.2022.5447.
No abstract available

Plain language summary

This Viewpoint discusses the need for assessing the risk of hereditary breast and ovarian cancer in individuals seeking gender-affirming surgery and referring eligible patients to genetic counseling and testing services before surgery.

MeSH terms

  • Breast Neoplasms* / surgery
  • Female
  • Genetic Counseling
  • Genetic Predisposition to Disease
  • Genetic Testing
  • Humans
  • Ovarian Neoplasms* / epidemiology
  • Ovarian Neoplasms* / surgery
  • Risk
  • Sex Reassignment Surgery*